PROMISE II: Percutaneous Deep Vein Arterialization for the Treatment of Late-Stage Chronic Limb-Threatening Ischemia

Not Applicable

Active, not recruiting

• Conditions: Peripheral Artery Disease; Chronic Limb-Threatening Ischemia; Critical Lower Limb Ischemia; Arterial Occlusion; Critical Limb Ischemia; Arterial Disease; Peripheral Artery Occlusion; Peripheral Vascular Disease; Vascular Diseases; Peripheral Arterial Disease
• Interventions: Device: LimFlow System

• Registration Number: NCT03970538
• Lead Sponsor: LimFlow, Inc.

Brief Summary

The LimFlow System is intended for endovascular, minimally invasive procedures in patients who have a clinical diagnosis of chronic limb-threatening ischemia and who have been determined to have no surgical or endovascular treatment option (i.e., "no option").

Detailed Description

The objective of this US pivotal trial is to investigate the safety and effectiveness of The LimFlow System for creating an AV connection in the Below The Knee (BTK) vascular system using an endovascular, minimally invasive approach to arterialize the pedal veins for the treatment of chronic limb-threatening ischemia (CLTI) in subjects ineligible for conventional endovascular or surgical limb salvage procedures.

Study Timeline

• Study First Submitted: 2019-05-29
• Study First Submitted QC: 2019-05-29
• Study First Posted: 2019-05-31
• Study Start: 2019-12-06
• Primary Completion: 2022-09-09
• Results First Submitted: 2023-12-20
• Status Verified: 2024-01
• Results First Submitted QC: 2024-01-30
• Last Update Submitted: 2024-01-30
• Results First Posted: 2024-02-28
• Last Update Posted: 2024-02-28
• Study Completion: 2025-02-28

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 105

Inclusion Criteria

1. Subject must be ≥18 and ≤ 95 years of age

2. Clinical diagnosis of chronic limb-threatening ischemia, defined as any of the following clinical assessments: previous angiogram or hemodynamic evidence of severely diminished arterial inflow of the index limb (e.g., ABI ≤ 0.39, TP / TcPO2 < 30 mm Hg) and

   1. Rutherford Classification 5, ischemic ulceration or
   2. Rutherford Classification 6, ischemic gangrene

3. Subject has been assessed by the principal investigator, reviewed by the Independent Review Committee (IRC), and determined that no conventional distal bypass surgical or endovascular therapy for limb salvage is feasible due to either a) absence of a usable pedal artery target (endovascular or surgical approach), or b) the presence of a pedal artery target with absence of a viable single-segment vein in either lower extremity or either arm that could be used for autogenous vein conduit.

4. Proximally, the Target In-flow Artery at the cross-over point must fall within the recommended vessel diameter ranges for the LimFlow stent graft by visual estimation.

5. Prior stent(s) to the infrainguinal arteries (e.g. iliac, SFA, and popliteal) are allowed.

6. Planned minor amputation (e.g. partial toe, ray or proximal foot/transmetatarsal) of target extremity within 30 days after the index procedure is allowed.

7. Subject is willing and able to sign the informed consent form.

8. Subject is enrolled in an acceptable wound care network and has an adequate support network to ensure that subject is compliant with medication regimen and follow-up study visits.

9. Prior to enrollment (7-day window), women of childbearing potential must have a negative pregnancy test.

10. Primary wound is stable (e.g. not rapidly deteriorating and/or showing signs of healing)

11. Stable glycemic control, HbA1C < 10% (<269mg/dL)

12. Subjects requiring dialysis may be included, provided they meet all the following requirements:

    • On dialysis for > 6 months
    • Autologous arteriovenous (AV) fistula or peritoneal access used for hemodialysis
    • Serum albumin > 30 g/liter
    • BMI > 20

Exclusion Criteria

1. Subjects will be excluded from participating in this study if they meet any of the following criteria prior to initiation of the endovascular procedure: Concomitant hepatic insufficiency, thrombophlebitis in the target limb, or non-treatable coagulation disorder within the past 90 days.
2. Active immunodeficiency disorder or currently receiving immunosuppressant therapy for an immunodeficiency disorder.
3. Prior peripheral arterial bypass procedure above or below the knee which would inhibit proximal inflow to the stent graft or interventional revascularization procedure within 30 days.
4. Previous major amputation of the target limb or presence of a wound requiring a free flap or absence of adequate viable tissue.
5. Life expectancy less than 12 months.
6. Documented myocardial infarction or stroke within previous 90 days.
7. Active infection (e.g. fever, significantly elevated WBC count >20.0 x 109/L, and/or positive blood culture) at the time of the index procedure that may preclude insertion of a prosthesis or require major amputation (e.g. osteomyelitis proximal to metatarsals).
8. Known or suspected allergies or contraindications to aspirin or P2Y12 inhibitors, heparin, stainless steel, nitinol or contrast agent that cannot be adequately pre-treated.
9. Subject is currently taking anti-coagulants, which in the opinion of the investigator, interferes with the subject's ability to participate in the study (i.e., intermittent interruption of therapy for procedure may compromise subject's safety).
10. Lower extremity vascular disease that may inhibit the procedure and/or jeopardize wound healing (e.g. vasculitis, Buerger's disease, significant edema in the target limb, deep venous thrombus in the target vein, hyperpigmentation, or medial ulceration above the ankle).
11. Significant acute or chronic kidney disease with a serum creatinine of > 2.5 mg/dl in subjects not undergoing dialysis.
12. Severe heart failure (e.g. NYHA Class IV), which in the opinion of the investigator may compromise subject's ability to safely undergo a percutaneous procedure.
13. Any significant concurrent medical, psychological, or social condition, which may significantly interfere with the subject's optimal participation in the study, in the opinion of the investigator.
14. The subject is currently participating in another investigational drug or device study that has not completed the primary endpoint or that clinically interferes with the endpoints of this study.
15. 15. Subject is unwilling, or unable, or unlikely for cognitive or social reasons to comply with any of the protocol or follow-up requirements.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Treatment Arm	LimFlow System	Treated with the LimFlow System

Primary Outcome Measures

Name	Time	Method
Amputation Free Survival (AFS)	6 months post-procedure	freedom from major amputation and death at 6 months, compared to a historical performance goal.

Secondary Outcome Measures

Name	Time	Method
Change in Rutherford Classification	6 months post-procedure	A change of one Rutherford class or greater.
Target Wound Healing	12 months post-procedure	Complete healing of the patient's target wound
Contrast Volume	During the procedure	Total volume of contrast media (measured in milliliters)
Primary Assisted Patency	6 months post-procedure	Absence of occlusion of the endovascular intervention maintained with the use of additional or secondary surgical or endovascular procedures, as long as occlusion of the primary treated site has not occurred.
Secondary Patency	6 months post-procedure	Absence of occlusion of the endovascular intervention that is maintained with the use of additional or secondary surgical endovascular procedures after occlusion occurs.
Technical Success	Immediately post-procedure	The successful creation of an arteriovenous fistula in the desired limb location with immediate morphological success.
Primary Patency	6 months post procedure	Absence of occlusion of the endovascular intervention that is maintained without the need for additional or secondary surgical or endovascular procedures.
All Wound Healing	12 months post-procedure	Complete healing of the patient's wounds.
Limb Salvage	6 months days post-procedure	The percentage of subjects with freedom from above-ankle amputation of the index limb.
Procedure Time	Immediately post-procedure	Time from the first puncture (venous or arterial) to when the last catheter is removed
Radiation Exposure	During the procedure	Patient radiation exposure (measured in milligray)
Procedure Success	30 days post-procedure	Combination of Technical Success, and absence of all-cause death, above-ankle amputation or clinically driven major re-intervention of the stent graft.
Freedom From Contrast-Induced Nephropathy	Within the first 72 hours post-procedure	Subjects without acute (within 72 hours after intravenous contrast administration) impairment of renal function, measured as an absolute ≥0.5 mg/dL (44 µmol/L) increase compared to baseline SCr value that results in a value above the upper limit of the normal range.
All Wound Area Reduction	12 months post-procedure	Defined as reduction in area of the patient's wounds

Trial Locations

Locations (21)

Boston Medical Center; 🇺🇸 Boston, Massachusetts, United States

Prisma Health -- Midlands; 🇺🇸 Columbia, South Carolina, United States

Harbor-UCLA Medical Center; 🇺🇸 Torrance, California, United States

The Cardiac and Vascular Institute; 🇺🇸 Gainesville, Florida, United States

University of Florida; 🇺🇸 Gainesville, Florida, United States

Unitypoint Health; 🇺🇸 Des Moines, Iowa, United States

Ochsner Health System; 🇺🇸 Kenner, Louisiana, United States

Massachusetts General Hospital; 🇺🇸 Boston, Massachusetts, United States

Saint Luke's Hospital; 🇺🇸 Lee's Summit, Missouri, United States

Dartmouth-Hitchcock Medical Center; 🇺🇸 Lebanon, New Hampshire, United States

New Mexico Heart Institute; 🇺🇸 Albuquerque, New Mexico, United States

Atrium Health; 🇺🇸 Charlotte, North Carolina, United States

Coastal Carolina Surgical Associates; 🇺🇸 Wilmington, North Carolina, United States

University Hospitals Cleveland Medical Center; 🇺🇸 Cleveland, Ohio, United States

Prisma Health -- Upstate; 🇺🇸 Greenville, South Carolina, United States

Seton Heart; 🇺🇸 Austin, Texas, United States

Baylor College of Medicine; 🇺🇸 Houston, Texas, United States

Ponce Medical School; 🇵🇷 Ponce, Puerto Rico

University of California San Francisco; 🇺🇸 San Francisco, California, United States

Vanderbilt University Medical Center; 🇺🇸 Nashville, Tennessee, United States

Yale University; 🇺🇸 New Haven, Connecticut, United States